fool.comAUG 232 min read$CAH

Cardinal Health's Pharma Chief Sold 7,354 Shares and Still Grew Her Stake by 47%. Here's How That Happened

Cardinal Health's (CAH) PSS Segment CEO Deborah Weitzman sold 7,354 shares at a weighted average price of $235.45, reducing her stake by 9%. She still holds 77,901 shares worth $18.31 million. Cardinal Health has a market cap of $55.0 billion and TTM revenue of $254.2 billion.

Original reporting

fool.com

Published Aug 23, 2026, 12:00 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 23, 2026, 12:19 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Cardinal Health's Pharma Chief Sold 7,354 Shares and Still Grew Her Stake by 47%. Here's How That Happened — source image — Source · fool.com

Decision brief

The 30-second read

$CAHNeutralLow

Why it matters

The insider sale provides fresh data on insider sentiment but is unlikely to drive major price moves.

Market read

Insider transaction adds modest new information; limited trading relevance.

What to watch

Potential tax planning or liquidity needs for the executive.

Relevance 5/10Novelty 5/10Timing: after market close

Background

Cardinal Health is a large healthcare services and products distributor with a $55B market cap.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CAHNeutralMedium confidence

Context

SEC Form 4 disclosed sale of 7,354 shares by segment CEO, reducing her stake by 9% to 77,901 shares.

Expected impact

Potential slight downward pressure, likely limited to short-term volatility.

Evidence & confidence

The $1.7M sale represents a small fraction of outstanding shares; market may price in modest impact.

Market effects

Sector

Minimal effect on healthcare distribution sector; peers unlikely to be impacted.

Regional

US market only; no regional ripple.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

Executive
Deborah Weitzman
CEO of the PSS Segment at Cardinal Health.

Read at source ← All news

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 3

$CAHHighAI 8/10

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.

insidermonkey.com3 min

AUG 19

$CAHHighAI 8/10

Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story

Cardinal Health (CAH) reported Q4 2026 earnings with non-GAAP EPS up 40% YoY to $2.91, including a $0.31 one-time tariff refund. Revenue reached $63.7B, up 6% YoY. Full-year adjusted free cash flow hit $5B. Guidance suggests slower growth ahead. The company expanded its buyback program by $5B to $6.4B.

yahoo.com2 min

AUG 18

$CAHHighAI 9/10

Cardinal Health (CAH) Q4 2026 Earnings Call Transcript

Cardinal Health (CAH) reported Q4 2026 revenue of $63.7B, up 6%, driven by Pharmaceutical and Specialty Solutions. Non-GAAP EPS was $2.91, up 40%. Fiscal 2027 guidance includes 3-5% pharma revenue growth and 8-11% profit growth. The company plans $1B in share repurchases and increased its authorization to $6.4B. Management cited risks from geopolitical instability and IRA price changes.

fool.com6 min

AUG 18

$CAHMed

5 Revealing Analyst Questions From Cardinal Health’s Q2 Earnings Call

Cardinal Health reported Q2 revenue of $63.67B, below Wall Street’s $65.42B estimate, but adjusted EPS of $2.60 beat the $2.42 estimate. Management cited demand in Pharmaceutical and Specialty Solutions and progress on its improvement plan in Global Medical Products and Distribution. Guidance for FY2027 adjusted EPS midpoint was $12.50. Analysts asked about specialty growth, M&A, regulatory impacts, and input costs.

financialcontent.com7 min

AUG 17

$BAXMed

Baxter’s interim CFO is leaving for Cardinal Health

Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

massdevice.com4 min